Notably, in the sub-group of IDH-mutant gliomas, a lower SUVmax was associated with a more favorable outcome (i.e., longer PRS and TTP), thus suggesting a potential of the tracer to stratify patients with homogeneous molecular profiling. This evidence concerns the gene IDH1 and central nervous system cancer.